Drug profile · INN
mycophenolate mofetil
CELLCEPT
mycophenolate mofetil (CELLCEPT) is a inosine-5'-monophosphate dehydrogenase (impdh) inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — mycophenolate mofetil
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 1
- Programs
- 71
- Data quality
- 0.89
Quick answer
mycophenolate mofetil (CELLCEPT) is a inosine-5'-monophosphate dehydrogenase (impdh) inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Primary target: Inosine-5'-monophosphate dehydrogenase (IMPDH)
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is mycophenolate mofetil?
mycophenolate mofetil (CELLCEPT) is a inosine-5'-monophosphate dehydrogenase (impdh) inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for mycophenolate mofetil?
CELLCEPT is a marketed brand name for mycophenolate mofetil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mycophenolate mofetil?
mycophenolate mofetil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.